Expertise in
2
conditions

Dr. Alireza Nami

Rheumatology
Joint And Muscle Medical Care PC
332 Lillington Ave, 
Charlotte, NC 
Accepting New Patients
Expertise in
2
conditions
Joint And Muscle Medical Care PC
332 Lillington Ave, 
Charlotte, NC 

Overview

Alireza Nami is a Rheumatologist practicing medicine in Charlotte, North Carolina.

Dr. Nami is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Fibromyalgia, Polymyalgia Rheumatica, and Rhizomelic Pseudopolyarthritis.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 7 clinical trials. Dr. Nami is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in NC

Hospital Affiliations

Carolinas Medical Center/behav Health
Novant Health Presbyterian Medical Center

Languages Spoken

English
Farsi
French

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Santa Clara Family Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Joint and Muscle Medical Care PC
332 Lillington Ave, Charlotte, NC 28204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Enrollment Status: Completed
Publish Date: March 20, 2026
Intervention Type: Other, Biological
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 6 Less Clinical Trials

2 Total Publications

Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.
Journal: The Lancet. Rheumatology
Published: June 25, 2020
Similar Doctors
Expertise in
50
conditions
Dr. Bob I. Wodecki
Rheumatology
Expertise in
50
conditions
Dr. Bob I. Wodecki
Rheumatology
Referral required
Before you request

Office

293 Old Mocksville Rd, 
Statesville, NC 
 (42.4 miles away)
Languages Spoken:
English, Polish
See accepted insurances
Accepting New Patients

Bob Wodecki is a Rheumatologist practicing medicine in Statesville, North Carolina. Dr. Wodecki is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Rheumatoid Lung Disease, Rheumatoid Pneumoconiosis, and Fibromyalgia. Dr. Wodecki is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required
Before you request

Office

1918 Randolph Rd Ste 600, 
Charlotte, NC 
 (1.1 miles away)
704-342-0252
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Laster is a Rheumatologist practicing medicine in Charlotte, North Carolina. Dr. Laster is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Osteoporosis, Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, and Axial Spondyloarthritis (AxSpA). Dr. Laster is currently accepting new patients.

Expertise in
12
conditions
Dr. Gordon K. Lam
Rheumatology
Expertise in
12
conditions
Dr. Gordon K. Lam
Rheumatology
Referral may be required
Before you request

Arthritis And Osteoporosis Consultant Carolinas PA

801 East Morehead Street, 
Charlotte, NC 
 (1.4 miles away)
704-342-0252
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gordon Lam is a Rheumatologist practicing medicine in Charlotte, North Carolina. Dr. Lam is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Eosinophilia-Myalgia Syndrome, Antisynthetase Syndrome, Dermatomyositis, and Rheumatoid Arthritis (RA). Dr. Lam is currently accepting new patients.

Frequently Asked Questions about Dr. Alireza Nami

Is Dr. Alireza Nami a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alireza Nami is classified as an Advanced expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Alireza Nami specialize in?

While Dr. Alireza Nami is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Fibromyalgia, and Polymyalgia Rheumatica. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Alireza Nami participate in research or clinical trials?

Yes. Dr. Alireza Nami has published 2 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Alireza Nami's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Alireza Nami accept my insurance?

Dr. Alireza Nami accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nami's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile